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New therapies for chronic obstructive pulmonary disease Peter J Barnes Chronic obstructive pulmonary disease non-selective drugs such as ipratropium brom-(COPD) is common, affecting 6% of men and ide and oxitropium bromide. M 1 receptors ap-4% of women over 45 years in the UK, and pear to be localised to parasympathetic ganglia there is evidence that it is increasing throughout and blockade of these receptors results in the world. It is responsible for 9% of certified reduced reflex bronchoconstriction. The sickness absence from work and imposes a large bronchoconstrictor action of acetylcholine in financial burden on the health service. COPD human airways is mediated entirely via M 3 has an increasing worldwide prevalence and receptors. By contrast, M 2 receptors located at now ranks fifth in terms of global burden of cholinergic nerve terminals inhibit the release disease. 1 Treatment is often unsatisfactory and of acetylcholine, thus acting as autoreceptors. 5 there are no currently available drug treatments Non-selective anticholinergics block M 1 and that influence its progressive course. There is M 3 receptors, leading to bronchodilatation, as a widespread therapeutic nihilism, so that many a result of relieving intrinsic cholinergic tone patients with COPD are undertreated while and inhibition of cholinergic reflex bronothers are treated as if they have asthma and choconstriction. However, by blocking prethis is often inappropriate. It is also important junctional M 2 receptors this leads to an increase to remember that 5-10% of patients with in acetylcholine release which may work against COPD have never smoked and therefore there the post-junctional blockade of M 3 receptors, are other causal mechanisms apart form ci-making these antagonists less efficient. It has garette smoking. been difficult to develop M 3 selective antIn contrast to the enormous increase in our agonists, but darifenacin (UK-88 525) is reunderstanding of the pathophysiology of ported to be M 3 selective and is in clinical asthma, relatively little attention has been paid development. 6 An M 1 /M 3 selective antagonist, to COPD. The chronic airflow obstruction is rispenzipine, has also been developed that does due to a combination of airway disease which not increase acetylcholine release, 5 but no clinparticularly affects small airways, and loss of ical studies have been reported. Another M 1 / lung elasticity due to enzymatic destruction of M 3 antagonist, revatropate (UK-112 166), the lung parenchyma. It is likely that the latter is in clinical development as a bronchodilator predominates in most patients and, while this for COPD. 6 The most promising drug is may be irreversible, it is likely to be preventable tiotropium bromide (Ba 679) which has the with suitable therapy.
unique property of kinetic selectivity, with rapid There have been some recent advances in dissociation from M 2 receptors and slow disthe therapy of COPD with improvement in sociation from M 1 and M 3 receptors. 7 8 Whether bronchodilator therapy which is the mainstay selective muscarinic antagonists will have adof management. However, there is a need for vantages over existing non-selective drugs rethe development of new therapies that prevent mains to be seen, however. the progressive airflow obstruction in this con-
The most important property of tiotropium dition.
bromide is its very long duration of action. It has a high affinity and dissociates very slowly from muscarinic receptors in human lung 9 and New bronchodilators produces long term blockade of muscarinic Bronchodilators play an important role in the receptors in human airway smooth muscle. 10 long term control of symptoms, but they do This is reflected by the prolonged blockade of not alter the progression of COPD. 2 The major cholinergic neural constriction in human and advances have been in the development of long guinea pig airways in vitro, with an effect lasting acting bronchodilators.
over eight hours in comparison with a duration of only one hour with ipratropium bromide. However, its effects on acetylcholine release are short lived and are similar to those seen   with atropine and ipratropium bromide, thus Anticholinergics are the bronchodilators of confirming functional selectivity for M 3 rather choice in the management of COPD and apthan M 2 receptors. In clinical studies inhaled pear to be more effective than 2 agonists. 
Department of
tiotropium bromide provides long term broncThere have been important advances in mus-noradrenergic activity, is reported to increase smoking cessation markedly. 22 In a recent study in which bupropion was given for seven weeks smoking cessation was 44% in the treatment group compared with 19% in the placebo group.
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Anti-inflammatory treatments COPD is characterised by inflammation of the airways. Bronchoalveolar lavage in patients with COPD shows increased numbers of neutrophils.
24 Bronchial biopsy specimens have demonstrated an infiltration with mononuclear cells, CD4+ and, particularly, CD8+ T lymphocytes rather than neutrophils, suggesting that neutrophils may transit rapidly from the circulation into the airway lumen.
25-28 Surprisingly, eosinophils may also be seen in stable COPD and increase to an even greater extent in exacerbations. 29 30 Biopsy specimens of ex- which suggests that, once established, inflammation may persist in the airway. 31 Induced sputum in patients with COPD shows a predominance of neutrophils, even in ex-smokers, ide will be suitable for once daily dosing. In phase III studies tiotropium bromide, given as in sharp contrast to the increased levels of eosinophils seen in patients with asthma. 32 a dry powder once daily, is well tolerated with no reported side effects and improves lung There is an increased concentration of TNFin the sputum 32 and this is consistent with function in patients with COPD.
14 It is likely that this drug will become the bronchodilator the finding of increased TNF--like immunoreactivity in the airways of patients with of choice for long term management of COPD, with the advantage of improved compliance COPD, particularly in exacerbations, and indicates that this cytokine may play a part in with once daily dosing. the inflammatory process. 27 30 The role of neutrophils in the lumen of COPD airways is not yet established, but it is likely that the   2  Recent studies have shown that the long acting release of enzymes such as neutrophil elastase and matrix metalloproteinases (MMP) may inhaled 2 agonists salmeterol and formoterol are beneficial in patients with COPD, resulting contribute to the pathophysiology of the disease (fig 1) . in improved lung function and symptom control. [15] [16] [17] These treatments may be a useful adThe mechanisms of the neutrophilic inflammation in COPD are not yet certain but dition to long acting anticholinergics. In one comparative study salmeterol given twice daily it is likely that neutrophil chemotactic factors are released into the airways from activated was significantly better in improving lung function and symptoms than ipratropium bromide macrophages and possibly from epithelial cells and CD8+ T lymphocytes. Macrophages may given four times daily. 18 play an important role in driving the inflammatory process in COPD and may release neutrophil chemotactic factors as well as proSmoking cessation Quitting smoking is the only strategy that has teolytic enzymes. Macrophage numbers are increased by 5-10-fold in the bronchoalveolar so far been shown to reduce the rate of decline in lung function in patients with COPD.
2 Less lavage fluid of patients with COPD and are concentrated in the centriacinar zones where than one third of patients are able to give up smoking, even with support. Nicotine replace-emphysema is most marked. Furthermore, the number of macrophages and T lymphocytes, ment therapy may help some patients and transdermal patches and inhaled nicotine may be the but not the number of neutrophils, in the alveolar wall is correlated with the amount of most effective delivery systems, 19 but continued administration of the addictive principle of ci-parenchymal destruction. 33 Macrophages may be responsible for the continued proteolytic garettes is an unpromising approach to smoking cessation and nicotine itself theoretically may activity in the lungs of patients with emphysema. IL-8 is selectively chemoattractant have adverse cardiovascular effects. Another approach is to develop nicotine receptor ant-to neutrophils and is present in high concentrations in induced sputum of patients with agonists. Behavioural intervention may be helpful in some patients. 20 Pharmacological COPD, whereas its concentrations in those with asthma are not significantly increased. 32 methods to reduce addictive behaviour have not so far been found to be effective and a Furthermore, there is a significant correlation between the concentration of IL-8 and the controlled trial of the anxiolytic buspirone showed no benefit. 21 The novel antidepressant extent of sputum neutrophilia which indicates that there may be a causal association. IL-8 bupropion (Zyban), which enhances central group.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from the sputum of patients with COPD. 32 Blocking of the CXC family (CXR1) and an additional unique receptor (CXR2). These chemokine receptors have the typical 7-transmembrane spanning structure common to G-protein may be secreted by macrophages, neutrophils, and by airway epithelial cells. 34 TNF-, which couples receptors. It may be possible to discover a non-peptidic inhibitor of these receptors is also increased in the airways and in induced sputum of patients with COPD, 27 30 32 may initi-by high throughput drug screening, but whether such drugs would be safe in long term ate the activation of the transcription factor nuclear factor-B (NF-B) which switches on dosing would require careful assessment. Another approach is to inhibit IL-8 synthesis. the transcription of the IL-8 gene.
35 Leukotriene B 4 (LTB 4 ) is also a potent chemotactic High concentrations of corticosteroids inhibit IL-8 gene transcription in airway epithelial agent for neutrophils in the airways 36 and is increased in the sputum of patients with cells, 47 yet neither inhaled nor oral steroids reduce IL-8 levels in the sputum of patients COPD 37 and alveolar macrophages from patients with 1 -antitrypsin deficiency secrete with COPD, suggesting that it is relatively resistant to steroid inhibition in vivo. greater amounts of LTB 4 . 38 Several approaches have been adopted to inhibit neutrophilic inChemokines such as IL-8 are induced by the transcription factor NF-B and there are flammation (table 1) .
several approaches to developing inhibitors for NF-B. 48 TNF-levels are raised in the sputum of patients with COPD and this cytokines in- Because there is continued neutrophilic in-duces IL-8 in airway cells. 34 Humanised TNF antibodies have now been developed for clinical flammation in COPD it was thought that inhaled corticosteroids might prevent the use and have been found to be effective in other chronic inflammatory diseases such as progression of the diseases. However, there is little evidence that inhaled corticosteroids are rheumatoid arthritis and Crohn's disease. 49 Soluble TNF receptors that bind up released TNF beneficial in COPD, 39 although there may be a few patients (>10%) who have some re-have also been developed and are in clinical trials. This approach might be effective in the sponse to steroids and these patients should probably be regarded as having concomitant treatment of COPD. asthma. In a small study there was no significant effect on lung function of inhaled budesonide   4 ( 4 )  with or without oral prednisolone in terms of LTB 4 is a potent chemoattractant of neutrophils lung function or decline in lung function. 40 A and its concentrations are increased in the recent large study (EUROSCOP) in patients sputum of patients with COPD, 37 probably with mild COPD showed no overall effect of being derived from alveolar macrophages. 38 inhaled steroids (budesonide 400 g twice Several LTB 4 receptor antagonists have now daily) on the annual rate of decline in lung been developed and have been studied in clinfunction, although some subgroups appeared ical trials of asthma and inflammatory bowel to benefit. 41 Neither inhaled nor oral steroids disease, but not yet of COPD. A potent LTB 4 have any significant effect on neutrophil counts, antagonist (LY 293 111) is ineffective against granule proteins, or inflammatory cytokines in allergen challenge in asthmatic patients, alinduced sputum, 42 43 which is consistent with though interestingly it inhibits neutrophil rea lack of effect of corticosteroids on disease cruitment into the airways during the late progression. However, there is a small effect response, indicating its capacity to inhibit on neutrophil chemotactic activity, presumably neutrophil chemotaxis in the airways. 50 Several mediated via an effect on macrophage or epi-other potent LTB 4 antagonists are now in dethelial cell function. This is in marked contrast velopment -for example, SC-53228, CPto their efficacy in asthma and their ability 105 696, and SB 201 146. LTB 4 is synthesised to reduce eosinophil counts in induced by the enzyme 5′-lipoxygenase (5-LO) of which sputum. 43 44 However, corticosteroids are there are now several potent inhibitors. 5-LO effective in treating acute exacerbations in inhibitors such as zileuton are now available in COPD, presumably via some as yet undefined some countries for the treatment of asthma, anti-inflammatory effect. 45 since they also inhibit the synthesis of cysteinyl leukotrienes, but it is not certain whether they are effective in COPD.   Several chemokines are involved in neutrophil chemotaxis. 46 These belong to the CXC family    Neutrophil recruitment into the lungs and resof chemokines, the most prominent member of which is IL-8 which is markedly increased in piratory tract is dependent on adhesion group.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from molecules expressed on neutrophils and endo-   Prostaglandin (PG) E 2 is a potent inhibitor of thelial cells in the pulmonary and bronchial circulations. Neutrophil adhesion in response the oxidative burst in neutrophils and its effects are mediated via EP 2 receptors. 61 Selective EP 2 to chemotactic factors is characterised by expression of the 2 integrins CD11a/CD18 agonists such as misoprostil and butaprost may therefore be effective in suppressing neutrophil (LFA-1) and CD11b/CD18 (Mac-1) on the surface of the neutrophil and their interaction activation but have not been studied in COPD.
Colchicine potently inhibits neutrophil acwith their counter receptors, including intercellular adhesion molecule-1 (ICAM-1), on tivation, enzyme release, and chemotaxis by disrupting cytoskeletal microtubule structure. endothelial cells. 51 E-selectin on endothelial cells also interacts with sialyl-Lewis on neutro-A controlled trial of colchicine in COPD showed some reduction in neutrophil elastase phils. Bronchial biopsy specimens of patients with COPD have shown increased expression activity 62 and in an observational study smokers who were treated with colchicine had a lower of E-selectin on vessels and ICAM-1 on epithelial cells. 52 Drugs that interfere with these annual decline in lung function than smokers not treated with colchicine. 63 adhesion molecules should therefore inhibit neutrophil inflammation in COPD. MonoMacrolide antibiotics such as erythromycin, clarithromycin, and roxithromycin have inclonal antibodies to CD18, ICAM-1, and Eselectin inhibit neutrophil accumulation in hibitory effects on neutrophil function that are independent of their antibiotic actions. 64 This animal models of lung inflammation. However, there are concerns about this therapeutic ap-may be through some ill defined membrane stabilising property and may account for the proach for a chronic disease as an impaired neutrophilic response may increase the sus-efficacy of macrolides in the treatment of diffuse panbronchilitis, with a reduction in neutroceptibility to infections. Indeed, a congenital deficiency of 2 integrins results in leucocyte philic inflammation and elastase activity in bronchoalveolar lavage fluid. 65 adhesion deficiency syndrome characterised by repeated septicaemia.

Surfactant is important for preventing airway   Inhibition of phosphodiesterases (PDE) in-closure, but also has immunomodulatory effects and is important for normal mucociliary creases the cyclic AMP content of neutrophils, resulting in reduced chemotaxis, activation, clearance. Cigarette smoking reduces surfactant production and this may contribute to degranulation, and adherence. [53] [54] [55] The predominant isoenzyme is PDE4 and several the detrimental effects of cigarette smoking on airway function. 66 This suggests that exogenous PDE4 inhibitors are now in clinical development for asthma. 56 It is not yet certain surfactant therapy might be beneficial in COPD, but the high cost of currently available whether these drugs will be useful and many of the first generation PDE4 inhibitors have preparations has made clinical studies difficult.
There are reports that ambroxol increases been limited by side effects such as nausea. In second generation PDE4 inhibitors such as surfactant secretion in lungs of experimental animals 67 but this has not been demonstrated SB 207 499 this may be less of a problem. Theophylline is a weak and non-selective PDE in patients with COPD. 68 inhibitor and has inhibitory effects on neutrophil function in vitro. 53 Aminophylline has an inhibitory effect on neutrophil chemotaxis in Antiproteases There is considerable evidence that, in patients vitro. 57 A recent study suggests that theophylline treatment in patients with COPD re-with COPD, there is an imbalance between proteases that digest elastin and those that duces neutrophil counts in induced sputum. 58 Pentoxyphylline is another non-selective PDE protect against this. 69 This suggests that either inhibiting these proteolytic enzymes or ininhibitor in clinical use that inhibits experimental neutrophil migration into the lungs, creasing antiproteases may be beneficial and theoretically should prevent the progression of but it has not been evaluated in COPD. PDE4 inhibitors may also be effective because they not airflow obstruction in COPD (table 2). Considerable progress has been made in identifying only have direct effects on neutrophil functions, but by inhibiting the release of chemotactic the enzymes involved in elastolytic activity in emphysema and in characterising the endofactors from alveolar macrophages. Again, PDE4 is the predominant subtype of PDE in genous antiproteases that counteract this activity. human alveolar macrophages. 59 60    Neutrophil elastase, a neutral serine protease, 73 74 These enzymes such as neutrophil elastase. It may be possible to prevent this induction with specific drugs inhibit neutrophil elastase-induced lung injury in experimental animals, whether given transcription inhibitors. Another approach is to develop specific inhibitors. Tetracyclines and by inhalation or systemically, 73 and inhibit neutrophil elastase-induced mucus secretion hydroxamates such as batimastat (BB-94) and the orally active marimastat (BB-2516) are in vitro. 75 There are few clinical studies with neutrophil elastase in patients with COPD. non-selective MMP inhibitors. 86 Broad spectrum MMP inhibitors also inhibit an enzyme, One study with oral MR889 administered for four weeks showed no overall effect on plasma TNF convertase, that inhibits the release of active TNF-which may be an additional benelevels of elastin-derived peptides or urinary levels of desmosine (markers of elastolytic ac-ficial property. Side effects of such drugs may be a problem. More selective inhibitors of intivity), but these may not be sensitive markers. 76 Although neutrophil elastase is likely to be dividual MMPs such as gelatinase B and macrophage metalloelastase are now in dethe major mechanism mediating elastolysis in patients with 1 -antitrypsin ( 1 -AT) deficiency, velopment and are likely to be better tolerated in chronic therapy. However, it is still not clear it may well not be the major elastolytic enzyme in smoking related COPD and it is important to whether there is one predominant MMP in COPD or whether a broad spectrum inhibitor consider other enzymes as targets for inhibition.
would be preferable.
 
Neutrophil elastase is not the only proteolytic 1 - The association of 1 -AT deficiency with emenzyme secreted by neutrophils. Cathepsin G and proteinase 3 have elastolytic activity and physema suggested that this endogenous inhibitor of neutrophil elastase may be of may need to be inhibited together with neutrophil elastase. Cathepsins (cathepsins B, L and therapeutic benefit in COPD. Cigarette smoking may inactivate 1 -AT, resulting in un-S) are also released from macrophages. Recently it has been found that suramin, a hexa-opposed activity of neutrophil elastase and cathepsins. Extraction of 1 -AT from human sulphonated naphthylurea which has been used as an anti-tumour drug, is a potent inhibitor plasma is very expensive and extracted 1 -AT is only available in a few countries (USA and of cathepsin G, proteinase 3, and neutrophil elastase. 77 Germany). This treatment has to be given intravenously and has a half life of only five days. This has led to the development of inhaled formulations.
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Nebulised 1 -AT reduces    Matrix metalloproteinases (MMPs) are a group neutrophil elastase activity in patients with cystic fibrosis. 88 However, inhaled 1 -AT is inof over 20 closely related endopeptidases that are capable of degrading all of the components efficient and expensive and could only be indicated in patients with severe 1 -AT deficiency. of the extracellular matrix of lung parenchyma, including elastin, collagen, proteoglycans, la-Recombinant 1 -AT with amino acid substitutions to increase stability may result in a minin and fibronectin. They are produced by neutrophils, but also by alveolar macro-more stable product. Gene therapy is another possibility using an adenovirus vector or lipophages. 78 Airway epithelial cells may also release MMPs. 79 Recently, increased levels of somes, but there have been major problems in developing efficient delivery systems. There is collagenase (MMP-1) and gelatinase B (MMP-9) have been reported in bronchoalveolar a particular problem with gene transfer in 1 - AT deficiency in that large amounts of protein lavage fluid of patients with emphysema. 80 Bronchoalveolar macrophages from patients (1-2 g) need to be synthesised each day.
Human 1 -AT has now been available for over with emphysema express more gelatinase B and collagenase than cells from control subjects, 10 years but even in patients with severe 1 -AT deficiency and emphysema there is only a suggesting that these cells rather than neutrophils may be the major source of these MMPs. 81 marginal effect on the rate of decline in FEV 1 . 89 There is no evidence that 1 -AT treatment Alveolar macrophages also express a unique MMP, macrophage metalloelastase (MMP-would halt the progression of COPD and emphysema in patients with normal plasma levels. 12), 82 which plays a key role in murine models of emphysema. 83 MMP-12 knock-out mice do Other serum protease inhibitors (serpins) such as elafin may also be important in counnot develop emphysema and do not show the expected increases in lung macrophages after teracting elastolytic activity in the lung. Elafin, an elastase-specific inhibitor, is found in long term exposure to cigarette smoke as occurs in normal animals. 84 Tissue inhibitors of metal-bronchoalveolar lavage fluid and is synthesised by epithelial cells in response to inflammatory loproteinases (TIMP) are endogenous inhibitors of these potent enzymes and three stimuli. 90 Serpins may not be able to inhibit neutrophil elastase at the sites of elastin dedifferent TIMPs have now been characterised.
There are several approaches to inhibiting struction due to the tight adherence of the inflammatory cell to connective tissue.
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MMPs. 85 One approach is to enhance the secretion of TIMPs and another is to inhibit the Furthermore, these proteins may become inactivated by the inflammatory process and the induction of MMPs in COPD. MMPs may show increased expression with cigarette smok-action of oxidants so that they may not be able group.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from to counteract elastolytic activity in the lung   Oxidative stress may result in the non-enadequately unless used in conjunction with other therapies. 92 zymatic formation of prostanoid mediators (isoprostanes) directly from arachidonic acid without the involvement of cyclo-oxygenase. 103 There is increased formation of isoprostanes in    cigarette smokers 104 and one isoprostane (8-Secretory leukoprotease inhibitor (SLPI) is a epi-prostaglandin F 2 ) is a potent constrictor 12 kDa serpin that appears to be a major of human airways, acting via stimulation of inhibitor of elastase activity in the airways. It thromboxane (TP) receptors. 105 This suggests is secreted by epithelial cells 90 and its secretion that thromboxane receptor antagonists such as is increased by corticosteroids. 93 In vitro re-seratrodast and Bay u3405 might be beneficial combinant human SLPI is more effective at in COPD. inhibiting neutrophil mediated proteolysis than
The role of prostaglandins in COPD is un-1 -AT. 94 Recombinant human SLPI given by known. Inhalation of the cyclo-oxygenase inaerosolisation increases SLPI and anti-hibitor indomethacin is reported to reduce neutrophil elastase activity in epithelial lining mucus hypersecretion in patients with fluid for over 12 hours, indicating potential COPD. 106 In patients with bronchiectasis indotherapeutic usefulness. 95 methacin has an inhibitory effect on chemotaxis of peripheral neutrophils but no effect on neutrophils in sputum. 107 It is likely that such an effect may be mediated via inducible cycloMediator antagonists  oxygenase (COX-2), and selective COX-2 inhibitors such as meloxicam and NS-398, which There is considerable evidence that oxidative stress is increased in patients with COPD and may have a reduced tendency to cause gastrointestinal problems, are now in clinical dethat reactive oxygen species contribute to its pathophysiology. 96 Oxidants are present in ci-velopment. garette smoke and are produced endogenously by activated inflammatory cells including neutrophils and alveolar macrophages. In-Pulmonary vasodilators Pulmonary hypertension due to chronic hypcreased production of endogenous oxidants is demonstrated by the increased levels of hy-oxia is a late complication of COPD in some patients and leads to cor pulmonale. There drogen peroxide (H 2 O 2 ) in expired condensates from patients with COPD, particularly during are no vasodilators that are selective for the pulmonary rather than the systemic circulation, exacerbations.
97 There is also increased production of nitric oxide in exhaled air. 98 Oxidants so that vasodilator therapy with current agents is potentially hazardous due to systemic hypomay contribute to the pathophysiology of COPD in several ways, including damage of tension. 108 The development of selective pulmonary vasodilators depends on selective serpins, potentiation of elastase activity, and increased mucus secretion. In addition, oxi-delivery via the inhaled route or the development of drugs that inhibit the mechanism dants activate the transcription factor NF-B which orchestrates the transcription of many of hypoxic constriction and structural remodelling that occur in secondary pulmonary inflammatory genes including IL-8 and inducible NO synthase. 35 hypertension. While prevention of structural remodelling is desirable, it is not certain This suggests that antioxidants may be of use in the treatment of COPD. N-acetyl cysteine whether relief of hypoxic vasoconstriction may worsen the chronic hypoxia in COPD by in-(NAC) provides cysteine for enhanced production of glutathione (GSH) and has anti-creased shunting. oxidant effects in vitro and in vivo. NAC inhibits endotoxin-induced neutrophilic inflammation in rat lungs through inhibition of   Beraprost, an orally active form of prostacyclin, NF-B. In clinical studies NAC reduces the number of exacerbations of COPD 99 and in an is more stable and has been reported to have a beneficial effect in pulmonary hypertension. 109 uncontrolled study appeared to reduce the rate of decline in FEV 1 over a two year period.
100
Nebulised prostacyclin and its more stable analogue, iloprost, are also reported to be effective Although epidemiological studies have linked COPD to poor intake of dietary antioxidants and the inhaled route appears to reduce the systemic side effects seen with intravenous prosuch as vitamins C and E, there have been no controlled trials of these vitamins in the stacyclin. It is likely that more effective antioxidants will be developed for clinical use in the future.    Inhaled nitric oxide (NO) has been used for Spin trap antioxidants such as -phenyl-N-tertbutyl nitrone are much more potent and inhibit some time as a selective pulmonary vasodilator due to its short duration of action and inthe formation of intracellular reactive oxygen species by forming stable compounds. 101 These activation in the systemic circulation 111 but it is difficult to use over a prolonged period. compounds are effective in animal models of oxidative stress. 102 They are now entering clin-Several NO donor compounds have been developed but suffer from the disadvantage that ical trials and their use in COPD should be considered.
they cause systemic vasodilatation.
group.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from rapid decline in FEV 1 and increased hospitalisation of patients with COPD. 119 This suggests that it may be important to develop drugs that inhibit the hypersecretion of mucus, although it will be important to find drugs that do not suppress the normal mucus secretion and impair mucociliary clearance. There are several types of mucoregulatory drugs in development.
 
Tachykinins are potent stimulants of mucus secretion from submucosal glands and goblet cells in human and animal airways and act via NK 1 receptors. 120 121 In animal studies cigarette a local axon reflex mechanism. 122 NK 1 antagonists markedly inhibit neurogenic mucus secretion 123 and may therefore be useful as mucoregulators in cigarette smoke induced   Endothelin has potent constrictor effects on chronic bronchitis. Several potent non-peptide NK 1 receptor antagonists such as CP-99 994 airway and pulmonary vascular smooth muscle and may play a role in COPD as its synthesis and SR 140 333 are now in clinical development and, while it is unlikely that they is increased by hypoxia. 112 Endothelin-1 (ET-1) is strongly expressed in the pulmonary vascular will be useful in asthma, they might have a role as regulators of mucus hypersecretion in endothelium of patients with pulmonary hypertension secondary to chronic hypoxia 113 and COPD. A clinical trial of a non-selective peptide tachykinin antagonist FK-224 appeared to urinary ET-1 excretion is increased in patients with COPD. 114 ET-1, acting mainly via ET A show some clinical benefit in patients with COPD, with a decrease in mucus production receptors, induces fibrosis and hyperplasia of pulmonary vascular smooth muscle, implying and coughing. 124 a role in the pulmonary hypertension secondary to COPD. This suggests that ET-1 antagonists may prevent the development of pulmonary     Another approach to blocking tachykinin-mehypertension. Potent orally active non-peptide endothelin antagonists such as bosentan and diated effects is to inhibit the release of tachykinins from sensory nerve endings via activation SB 217 242 have now been developed. The non-selective antagonist bosentan and the ET A of pre-junctional receptors (fig 2) . 125 Of these receptors, -opioid receptors are most effective receptor antagonist BQ123 inhibit the development of pulmonary hypertension in rats and the -opioid agonist morphine potently inhibits cigarette smoke-induced mucus seafter chronic hypoxia. 115 116 Potent non-peptide selective orally active ET A antagonists such as cretion in animal airways. 126 In human airways in vitro morphine inhibits mucus secretion ac-PD 156 707 have also now been developed. tivated via stimulation of sensory nerves. 127 While morphine itself may not be useful as a therapeutic agent because of addiction, peri-  Angiotensin II is a potent pulmonary and air-pherally acting opioid agonists that do not cross the blood brain barrier, such as BW443, might way constrictor acting via angiotensin (AT) receptors. Non-peptide inhibitors of AT 1 re-be of use.
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Many pre-junctional receptors appear to opceptors such as losartan have now been developed. Losartan inhibits hypoxic pulmonary erate via the opening of a common potassium (K) channel, suggesting that K channel openers vasoconstriction and the remodelling that occurs in the pulmonary circulation after chronic may be useful in blocking mucus secretion.
Openers of ATP-dependent K channels such hypoxia. 117 Losartan reduces pulmonary artery pressure in patients with COPD 118 and there-as cromakalim do, indeed, have an inhibitory effect on cigarette smoke-induced mucus sefore may be useful in preventing the progression of pulmonary hypertension and cor pulmonale cretion in animals. 129 in patients with severe COPD. An AT 2 receptor antagonist PD 123 319 does not appear to affect the pulmonary response to hypoxia. 117     Many mediators stimulate mucus secretion from submucosal glands and/or goblet cells and may therefore contribute to increased mucus Mucoregulators Increased secretion of mucus is found in all secretion in COPD. It is unlikely, however, that any mediator antagonists such as antipatients who smoke heavily, irrespective of airflow obstruction. However, recent epi-leukotrienes would have a major effect on mucus secretion. As noted above, neutrophil demiological data suggest that mucus hypersecretion is significantly associated with a more elastase and other proteases are potent stimgroup.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from ulants of submucosal gland and goblet cell resulting from proteolytic destruction of lung parenchyma, it seems unlikely that this could secretion, suggesting that protease inhibitors may have inhibitory effects on mucus secretion, be reversible by drug therapy, although it might be possible to reduce the rate of progression as well as inhibiting lung destruction. As noted above, inhalation of the cyclo-oxygenase in-by preventing the inflammatory and enzymatic disease process. Retinoic acid increases the hibitor indomethacin is reported to reduce mucus hypersecretion in patients with number of alveoli in developing rats and, remarkably, reverses the histological and COPD 106 but long term trials of COX inhibitors have not been undertaken.
physiological changes induced by elastase treatment. 137 Retinoic acid activates retinoic acid receptors which act as transcription factors to regulate the expression of many genes. The    Several MUC genes that code for mucin syn-molecular mechanisms involved and whether this can be extrapolated to humans is not yet thesis have now been cloned.
130 MUC2 and MUC5AC appear to be particularly important known. Several retinoic acid receptor subtype agonists have now been developed that may in airway mucus and MUC5AC may be upregulated by inflammatory cytokines and in-have a greater selectivity for this effect. hibited by glucocorticoids. 131 It is possible that drugs may be developed that inhibit the abnormally increased expression of MUC genes Delivery systems Bronchodilators are currently given as inhalers, (predominantly MUC5AC in COPD) while preserving baseline secretion of MUC2. Such either metered dose inhalers or dry powder inhalers, that have been optimised to deliver drugs, other than steroids, have not yet been developed.
drugs to the respiratory tract. However, in emphysema the inflammatory process takes place in the lung parenchyma. This implies that a drug to be delivered by inhalation should have   Several drugs were developed to reduce vis-a lower mass median diameter so that there is preferential deposition in the lung periphery. cosity of mucus, thus aiding clearance from the respiratory tract. These drugs include cysteine It may be more appropriate to give the drug parenterally as it will need to reach the lung derivatives such as N-acetyl cysteine, methyl cysteine, and carbocisteine which were effective parenchyma via the pulmonary circulation, but parenteral administration may increase the risk in reducing mucus viscosity in vitro, but there is little convincing evidence that they increase of systemic side effects. mucus clearance in patients with COPD. DNAse also reduces sputum viscosity, particularly when sputum is infected, as DNA Future directions
There is a pressing need for the development is a major determinant of sputum viscosity. Although nebulised recombinant human of new drugs for the treatment of COPD. While preventing and quitting smoking is the obvious DNAse (dornase alfa) appears to improve the rheological properties of mucus in patients with preferred approach, this has proved to be very difficult in the majority of patients. In addition, cystic fibrosis, 132 this has not been reported in COPD. It is possible that more effective it is likely that the inflammatory process initiated by cigarette smoking may continue even mucolytic agents will be developed in the future.
when smoking has ceased. Furthermore, approximately 10% of patients with COPD are non-smokers. COPD may be caused by other environmental factors (pollutants, passive   Erythromycin inhibits mucin secretion from smoking, other inhaled toxins) or by development changes in the lungs. human airways in vitro and appears to be interactive with dexamethasone. 133 Erythromycin It is important to identify the factors that determine why only 15% of smokers develop and clarithromycin also reduce endotoxin-induced mucus discharge from goblet cells in COPD. So far this is little understood, although it is likely that genetic factors are important. 138 guinea pig trachea. 134 This property does not appear to be related to its antibiotic activity The only clearly established genetic risk factor for COPD is the ZZ allele of the 1 -antitrypsin and is consistent with other studies demonstrating an inhibitory action of erythromycin gene, although heterozygotes may be at slightly increased risk. There are also weak associations on cell secretion. There is a clinical case report of the efficacy of erythromycin in treating with 1 -antichymotrypsin, 2 -macroglobulin, and vitamin D binding protein. A polymucus hypersecretion, 135 and clarithromycin has been reported to reduce nasal secretion of morphism in the gene for the enzyme microsomal epoxide hydrolase responsible for the mucus in patients with rhinitis. 136 This suggests that the molecular mechanisms involved in metabolism of reactive epoxide intermediates which may be generated in tobacco smoke has these effects need to be defined and that studies in COPD may be indicated.
recently been found to be associated with a 4-5 fold increased risk of COPD and emphysema. 139 It is likely that many other genetic polymorphisms will be discovered that will conDrugs affecting remodelling Since a major mechanism of airway obstruction fer risk on smokers for the development of COPD and emphysema, so that it will evenin COPD is caused by loss of elastic recoil 
